LEVETIRACETAM TEVA ® 250 MG

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

LEVETIRACETAM 250 MG

Dostępny od:

TEVA PHARMACEUTICAL INDUST.LTD

Kod ATC:

N03AX14

Forma farmaceutyczna:

TABLETS

Droga podania:

PER OS

Wyprodukowano przez:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupa terapeutyczna:

LEVETIRACETAM

Wskazania:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Data autoryzacji:

2009-09-01